Search

Displaying results 2151 - 2160 of 10000 in total
  1. Drug

    Conestat alfa

    go.drugbank.com/drugs/DB09228
    Approved

    Down-stream effects of the lack of enzyme inhibition by C1 esterase inhibitor results in swelling due to leakage of fluid from blood vessels into connective tissue and consequently the presentation of

  2. Drug

    Denufosol

    go.drugbank.com/drugs/DB04983
    Investigational

    Denufosol has not gained FDA approval, and clinical trials with this drug have ceased since 2011. … A new drug application (NDA) was filed with the FDA in 2011, however, the second phase III clinical trial showed a lack of improvement in lung function for cystic fibrosis patients taking denufosol.

  3. Drug

    Zuranolone

    go.drugbank.com/drugs/DB15490
    ApprovedInvestigational

    [A260791] Zuranolone was approved by the FDA on August 4th, 2023, and it is currently the only approved treatment for women with postpartum depression. … more common GABA<sub>A</sub> positive allosteric modulators on the market like benzodiazepines, zuranolone can modulate both synaptic and extrasynaptic GABA<sub>A</sub> conductance due to binding to a non-benzodiazepine

  4. Drug

    Omacetaxine mepesuccinate

    go.drugbank.com/drugs/DB04865
    ApprovedInvestigationalWithdrawn

    In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. … Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors

  5. Drug

    Fospropofol

    go.drugbank.com/drugs/DB06716
    ApprovedIllicitInvestigationalWithdrawn

    Unlike propofol, does not cause injection-site pain as it is unable to activate TRPA1. FDA approved in December 2008.

  6. Drug

    Uric acid

    go.drugbank.com/drugs/DB08844
    Investigational

    At present (August 2013), there is no approved formulation or indication for uric acid. … Normally a small amount of uric acid is present in the body, but when there is an excess amount in the blood, called hyperuricemia, this can lead to gout and formation of kidney stones.

  7. Drug

    Ifosfamide

    go.drugbank.com/drugs/DB01181
    ApprovedInvestigational

    Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

    Products: IFO-CELL N 1000, IFO-cell N 1000; Solution for Infusion (1000mg per vial)
  8. Drug

    Maribavir

    go.drugbank.com/drugs/DB06234
    ApprovedInvestigational

    Maribavir was approved by the FDA in November 2021, under the name Livtencity (Takeda), for the treatment of resistant CMV infections in post-transplant patients. … [L39327] The drug was also approved by Health Canada in September 2022 [L43262] and by European Commission in November 2022.[L44411]

  9. Drug

    Lisdexamfetamine

    go.drugbank.com/drugs/DB01255
    ApprovedInvestigational

    [A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009. … [L48285] Lisdexamfetamine works to treat attention deficit hyperactivity disorder and binge eating disorder [A2230] by blocking dopamine and norepinephrine reuptake and increasing their levels in the extraneuronal

  10. Drug

    Teprotumumab

    go.drugbank.com/drugs/DB06343
    ApprovedInvestigational

    Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and was approved by